Drugs & Targets Mayo Clinic collaborates with Morphotek in triple-negative breast cancer study. February 05, 2016Vol.42 No.05
Drugs & Targets FDA tells Telesta they need another phase III MCNA trial February 05, 2016Vol.42 No.05
Drugs & Targets Venetoclax Receives Third Breakthrough Designation from FDA February 05, 2016Vol.42 No.05
In Brief Van Andel Research Institute-SU2C Dream Team trial enters phase II February 05, 2016Vol.42 No.05
Capitol Hill FDA Releases New Opioid Plan as Senators Stall Robert Califf’s Confirmation as Commissioner February 05, 2016Vol.42 No.05By Conor Hale
